PSMD4 and hepatocellular carcinoma: Notably, MCB1 expression was higher in HCC tissues resistant to TACE, sorafenib, or lenvatinib therapy than in those sensitive to the treatments (Figure 1I–K), suggesting that MCB1 expression is closely associated with HCC chemoresistance.